Miach Orthopaedics post-marketing ACL study treats first patient
Photo | Courtesy
Miach Orthopaedics CEO Martha Shadan.
Miach Orthopaedics, a Westborough medical device company, announced Monday the first patient successfully treated in a post-marketing clinical trial for the company’s Bridge-Enhanced ACL Restoration implant, following its clearance from the U.S. Food & Drug Administration in December.
The BEAR implant facilitates healing of a torn ACL by acting like a bridge between the torn ends of the ligament and is absorbed by the body as the patient heals, per the company’s announcement.
The first patient, a 32-year-old male with a mid-substance ACL tear, was treated at MedStar Surgery Center at Timonium in Maryland. This outpatient site is affiliated with Medstar Union Memorial Hospital in Baltimore.
“The BEAR Implant is a promising new technology that could improve the way ACL tears are treated,” said Dr. Richard Levine, the orthopedic surgeon who performed the surgery.
CORRECTION: A previous version of this story incorrectly said Miach Orthopaedics treated the first patient with its Bridge-Enhanced ACL Restoration technology. The correct information is this marked the first patient treated in this study following the technology's clearance by the U.S. Food & Drug Administration.
WBJ Web Partners
Most Recent
Most Recent
0 Comments